Medication info
Ligarine Capsule 150 mg (Pregabalin)

Ligarine Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
(Co., Ltd.) HanKook Pharma
Appearance
A hard capsule with a white powder inside, white on the top and bottom
Packaging
30 capsules/bottle, 150 capsules/bottle
Approval status
Active

MFDS item code 201109237 · Notified 2011.10.27 · Insurance code 653004950

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This drug is administered orally as pregabalin in 2 divided doses per day, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin, initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin, initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin, initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin, initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: initial dose 25, maximum dose 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under method of administration. b: An additional dose refers to a supplemental dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
(Co., Ltd.) HanKook Pharma

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults, as an adjunct for partial seizures in epilepsy, and to help alleviate symptoms of fibromyalgia.

How to take

Adult dose

This drug is administered orally as pregabalin in 2 divided doses per day, with or without food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each individual patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Total daily dose of pregabalin, initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Total daily dose of pregabalin, initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Total daily dose of pregabalin, initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Total daily dose of pregabalin, initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: initial dose 25, maximum dose 100, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under method of administration. b: An additional dose refers to a supplemental dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so if symptoms of depression or mood changes occur while taking this medication, immediate medical assistance should be sought. Persons with an allergy to any components of this medication should not take it. Diabetic patients may experience weight gain after taking this medication, which may require adjustments to their blood sugar control medications. If symptoms of angioedema such as swelling of the face or mouth occur, use should be discontinued immediately. Elderly persons should be cautious when taking this medication as dizziness or drowsiness may increase, and they should be careful until they acclimate to these symptoms. This medication may cause blurred vision or changes in eyesight, so medical advice should be sought if symptoms occur. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, dosage should be reduced gradually according to medical advice. Patients with a history of drug abuse may require close monitoring due to the potential for dependence on this medication. Patients with impaired kidney function may need dosage adjustments. Patients with heart disease should use this medication cautiously as there may be a risk of heart failure. Using this medication with other drugs that have central nervous system depressant effects may increase the risk of drowsiness or respiratory depression. During early pregnancy, this medication may affect the fetus; therefore, women who are pregnant or planning to become pregnant must consult with their healthcare provider and use effective contraception. Breastfeeding women should carefully decide whether to breastfeed or take this medication, as it can be passed into breast milk. Before driving or operating hazardous machinery, it should be confirmed whether this medication causes dizziness or drowsiness. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatment such as hemodialysis may be necessary. This medication should be kept out of reach of children, and transferring it to another container may compromise its quality, so caution is advised.

Side effects

  • Suicidal impulses
  • suicidal behaviors
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 178 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • hypersalivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • ejaculation delay
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • gait abnormalities
  • falling
  • feeling drunk
  • unusual sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • directional sense disturbance
  • irritability
  • depression
  • relief
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • anxiety
  • mood swings
  • emotional decrease
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory decrease
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • speech disorders
  • benign essential tremor
  • decreased reflexes
  • abnormal movement
  • psychomotor agitation
  • position-related dizziness
  • hypersensitivity
  • burning sensation
  • active tremors
  • syncope
  • confusion
  • psychomotor retardation
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • diplopia
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • nasal bleeding
  • coughing
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • listlessness
  • shock
  • symptoms resembling anaphylaxis
  • mucocutaneous syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • mood disorders
  • drowsiness
  • confusional state
  • restlessness
  • restlessness
  • worsening of convulsions

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. The recommended storage temperature is between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a white powder inside, white on the top and bottom

Package unit

30 capsules/bottle, 150 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.